Mariner
MDGL icon

Mariner’s Madrigal Pharmaceuticals MDGL Stock Holding History

Mariner’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$296K Sell
567
-1,859
-77% -$888K ﹤0.01% 2886
2025
Q4 		$1.41M Buy
2,426
+605
+33% +$309K ﹤0.01% 1706
2025
Q3 		$835K Buy
1,821
+271
+17% +$101K ﹤0.01% 2045
2025
Q2 		$469K Sell
1,550
-334
-18% -$99.5K ﹤0.01% 2384
2025
Q1 		$624K Buy
1,884
+138
+8% +$45.3K ﹤0.01% 2022
2024
Q4 		$539K Sell
1,746
-1,252
-42% -$352K ﹤0.01% 2138
2024
Q3 		$636K Buy
2,998
+110
+4% +$28.1K ﹤0.01% 1942
2024
Q2 		$809K Buy
2,888
+255
+10% +$60.7K ﹤0.01% 1660
2024
Q1 		$703K Buy
2,633
+1,371
+109% +$323K ﹤0.01% 1770
2023
Q4 		$292K Buy
+1,262
New +$221K ﹤0.01% 2377
2023
Q1 		– Sell
-730
Closed -$212K – 2840
2022
Q4 		$212K Buy
+730
New +$71.4K ﹤0.01% 2310

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mariner's MDGL Position: Q1 2026 in Review

Mariner reduced its Madrigal Pharmaceuticals (MDGL) stake by 77% in Q1 2026, selling an estimated $888K and leaving 567 shares worth $296K. The position accounts for ﹤0.01% of the portfolio, ranked #2886.

Mariner first reported a position in MDGL in Q4 2022 and has held it in 11 quarters since. The position peaked at $1.41M in Q4 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Mariner held 567 shares of Madrigal Pharmaceuticals worth $296K as of Q1 2026.
  • Mariner sold 1,859 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $888K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #2886 holding.
  • Mariner first reported a position in Madrigal Pharmaceuticals in Q4 2022 and has held it in 11 quarters since.
  • Mariner's Madrigal Pharmaceuticals position peaked at $1.41M in Q4 2025.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.